Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst

Since Gilead Sciences unveiled a $21 billion buyout of Immunomedics centered on Trodelvy, industry watchers have been busy crunching the numbers. Now, after seeing new data, one analyst sees broad opportunity for the antibody-drug conjugate that justifies the purchase price.